SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2025
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	(18) SUBSEQUENT EVENTS ZMS On October 1, 2025, the Company announced a change to its commercialization strategy for its ZMS subsidiary, which develops noninvasive, laser-based patient-monitoring technologies acquired through the December 2021 acquisition of Kestrel Labs, Inc. The Company determined it would no longer independently commercialize NiCO. Instead, the Company plans to pursue commercialization through one or more strategic partners. As a result of the actions described above, the Company incurred pre-tax asset impairment charges of $30.7 million during the three months ended September 30, 2025, primarily related to the impairment of goodwill and other assets associated with the ZMS business (See Note 7 – Impairment). As part of this initiative, the Company implemented a workforce reduction within ZMS on October 1, 2025, eliminating substantially all positions and ceasing most internal R&D and manufacturing activities. On November 1, 2025, the Company eliminated all remaining positions within ZMS and ceased independent operations. The Company also expects to incur pre-tax cash charges of approximately $0.7 million associated with severance payments to former ZMS employees in the fourth quarter of 2025. Policy Change Effective October 1, 2025, the Company initiated a phased implementation of a resupply policy that requires patient confirmation of current need for supplies prior to initiating shipment and billing. The Company anticipates that the policy, which is effective October 1, 2025, for a majority of payers, including all public payers, will be rolled out to all remaining payers by the end of the quarter ending December 31, 2025. Other Subsequent Events Other than disclosed above, there were no additional subsequent events identified through November 17, 2025.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2025

(18) SUBSEQUENT EVENTS

ZMS

On October 1, 2025, the Company announced a change to its commercialization strategy for its ZMS subsidiary, which develops noninvasive, laser-based patient-monitoring technologies acquired through the December 2021 acquisition of Kestrel Labs, Inc. The Company determined it would no longer independently commercialize NiCO. Instead, the Company plans to pursue commercialization through one or more strategic partners.

As a result of the actions described above, the Company incurred pre-tax asset impairment charges of $30.7 million during the three months ended September 30, 2025, primarily related to the impairment of goodwill and other assets associated with the ZMS business (See Note 7 – Impairment). As part of this initiative, the Company implemented a workforce reduction within ZMS on October 1, 2025, eliminating substantially all positions and ceasing most internal R&D and manufacturing activities. On November 1, 2025, the Company eliminated all remaining positions within ZMS and ceased independent operations. The Company also expects to incur pre-tax cash charges of approximately $0.7 million associated with severance payments to former ZMS employees in the fourth quarter of 2025.

Policy Change

Effective October 1, 2025, the Company initiated a phased implementation of a resupply policy that requires patient confirmation of current need for supplies prior to initiating shipment and billing. The Company anticipates that the policy, which is effective October 1, 2025, for a majority of payers, including all public payers, will be rolled out to all remaining payers by the end of the quarter ending December 31, 2025.

Other Subsequent Events

Other than disclosed above, there were no additional subsequent events identified through November 17, 2025.